title: Positron emission tomography evaluation of somatostatin receptor targeted 64Cu-TATE-liposomes in a human neuroendocrine carcinoma mouse model.
abstract: Targeted therapeutic and diagnostic nanocarriers functionalized with antibodies, peptides or other targeting ligands that recognize over-expressed receptors or antigens on tumor cells have potential in the diagnosis and therapy of cancer. Somatostatin receptors (SSTRs) are over-expressed in a variety of cancers, particularly neuroendocrine tumors (NETs) and can be targeted with somatostatin peptide analogs such as octreotate (TATE). In the present study we investigate liposomes that target SSTR in a NET xenograft mouse model (NCI-H727) by use of TATE. TATE was covalently attached to the distal end of DSPE-PEG(2000) on PEGylated liposomes with an encapsulated positron emitter (64)Cu that can be utilized for positron emission tomography (PET) imaging. The biodistribution and pharmacokinetics of the (64)Cu-loaded PEGylated liposomes with and without TATE was investigated and their ability to image NETs was evaluated using PET. Additionally, the liposome accumulation and imaging capability was compared with free radiolabelled TATE peptide administered as (64)Cu-DOTA-TATE. The presence of TATE on the liposomes resulted in a significantly faster initial blood clearance in comparison to control-liposomes without TATE. PEGylated liposomes with or without TATE accumulated at significantly higher quantities in NETs (5.1±0.3 and 5.8±0.2 %ID/g, respectively) than the free peptide (64)Cu-DOTA-TATE (1.4±0.3 %ID/g) 24 h post-injection. Importantly, (64)Cu-loaded PEGylated liposomes with TATE showed significantly higher tumor-to-muscle (T/M) ratio (12.7±1.0) than the control-liposomes without TATE (8.9±0.9) and the (64)Cu-DOTA-TATE free peptide (7.2±0.3). The higher T/M ratio of the PEGylated liposomes with TATE suggests some advantage of active targeting of NETs, although no absolute benefit in tumor accumulation over the non-targeted liposomes was observed. Collectively, these data showed that (64)Cu-loaded PEGylated liposomes with TATE conjugated to the surface could be promising new imaging agents for visualizing tumor tissue and especially NETs using PET.
authors.affiliation: Technical University of Denmark, DTU Nanotech, Department of Micro- and Nanotechnology, Center for Nanomedicine and Theranostics, Building 423, 2800 Lyngby, Denmark.
authors.forename: Anncatrine L
authors.initials: AL
authors.lastname: Petersen
authors.forename: Tina
authors.initials: T
authors.lastname: Binderup
authors.forename: Rasmus I
authors.initials: RI
authors.lastname: Jølck
authors.forename: Palle
authors.initials: P
authors.lastname: Rasmussen
authors.forename: Jonas R
authors.initials: JR
authors.lastname: Henriksen
authors.forename: Andreas K
authors.initials: AK
authors.lastname: Pfeifer
authors.forename: Andreas
authors.initials: A
authors.lastname: Kjær
authors.forename: Thomas L
authors.initials: TL
authors.lastname: Andresen
mesh_terms: D000818:Animals; D018278:Carcinoma, Neuroendocrine / Q000000981:diagnostic imaging* / Q000378:metabolism; D045744:Cell Line, Tumor; D003301:Copper Radioisotopes; D005260:Female; D006801:Humans; D007553:Isotope Labeling; D008081:Liposomes; D051379:Mice; D008819:Mice, Nude; D015394:Molecular Structure; D015282:Octreotide / Q000031:analogs & derivatives* / Q000737:chemistry / Q000493:pharmacokinetics; D009942:Organometallic Compounds / Q000737:chemistry / Q000493:pharmacokinetics; D010714:Phosphatidylethanolamines / Q000737:chemistry / Q000493:pharmacokinetics; D049268:Positron-Emission Tomography / Q000379:methods*; D019275:Radiopharmaceuticals / Q000737:chemistry / Q000493:pharmacokinetics; D060888:Real-Time Polymerase Chain Reaction; D017481:Receptors, Somatostatin / Q000378:metabolism*; D014018:Tissue Distribution; D023041:Xenograft Model Antitumor Assays
chemical_list: C576034:1,2-distearoylglycero-3-phosphoethanolamine-N-(methoxy(polyethylene glycol)-2000)octreotate; C575629:64Cu-DOTATATE; D003301:Copper Radioisotopes; D008081:Liposomes; D009942:Organometallic Compounds; D010714:Phosphatidylethanolamines; D019275:Radiopharmaceuticals; D017481:Receptors, Somatostatin; D015282:Octreotide